Vivek Subbiah: How can we get cutting-edge clinical trials to more patients where they live in their own communities?
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Super excited visiting Denver for an amazing kick off meeting bringing together leaders in research from early phase units, & late phase centers discussing clinical trials spanning heme malignancies, & solid tumors.
How can we get cutting-edge clinical trials to more patients where they live in their own communities ?
Fantastic discussions & the future is bright in cancer research with multi-stakeholder engagement.”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023